PL3478679T3 - Pochodne 5,7-dihydro-pirolopirydyny do leczenia chorób neurologicznych i neurodegeneracyjnych - Google Patents
Pochodne 5,7-dihydro-pirolopirydyny do leczenia chorób neurologicznych i neurodegeneracyjnychInfo
- Publication number
- PL3478679T3 PL3478679T3 PL17733044T PL17733044T PL3478679T3 PL 3478679 T3 PL3478679 T3 PL 3478679T3 PL 17733044 T PL17733044 T PL 17733044T PL 17733044 T PL17733044 T PL 17733044T PL 3478679 T3 PL3478679 T3 PL 3478679T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrrolo
- dihydro
- neurodegenerative diseases
- pyridine derivatives
- treating neurological
- Prior art date
Links
- CSIRALAEFSXNQJ-UHFFFAOYSA-N C1CN=C2C=CN=C2C1 Chemical class C1CN=C2C=CN=C2C1 CSIRALAEFSXNQJ-UHFFFAOYSA-N 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357624P | 2016-07-01 | 2016-07-01 | |
| US201662372421P | 2016-08-09 | 2016-08-09 | |
| PCT/IB2017/053565 WO2018002760A1 (en) | 2016-07-01 | 2017-06-15 | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases |
| EP17733044.6A EP3478679B1 (en) | 2016-07-01 | 2017-06-15 | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3478679T3 true PL3478679T3 (pl) | 2021-10-25 |
Family
ID=59215839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17733044T PL3478679T3 (pl) | 2016-07-01 | 2017-06-15 | Pochodne 5,7-dihydro-pirolopirydyny do leczenia chorób neurologicznych i neurodegeneracyjnych |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US10604519B2 (OSRAM) |
| EP (2) | EP3478679B1 (OSRAM) |
| JP (1) | JP7046018B2 (OSRAM) |
| KR (1) | KR102470497B1 (OSRAM) |
| CN (1) | CN109641898B (OSRAM) |
| AU (1) | AU2017286868B2 (OSRAM) |
| CA (1) | CA2972070A1 (OSRAM) |
| DK (1) | DK3478679T3 (OSRAM) |
| ES (1) | ES2878160T3 (OSRAM) |
| HU (1) | HUE054857T2 (OSRAM) |
| IL (1) | IL263912B (OSRAM) |
| MX (1) | MX386258B (OSRAM) |
| PH (1) | PH12019500004A1 (OSRAM) |
| PL (1) | PL3478679T3 (OSRAM) |
| PT (1) | PT3478679T (OSRAM) |
| SG (1) | SG11201811712QA (OSRAM) |
| TW (1) | TWI736642B (OSRAM) |
| UY (1) | UY37311A (OSRAM) |
| WO (1) | WO2018002760A1 (OSRAM) |
| ZA (1) | ZA201900519B (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018226545A1 (en) * | 2017-06-09 | 2018-12-13 | Merck Sharp & Dohme Corp. | Azabicyclo[4.1.0]heptane allosteric modulators of the m4 muscarinic acetylcholine receptor |
| ES2937236T3 (es) * | 2017-06-22 | 2023-03-27 | Pfizer | Derivados de dihidro-pirrolo-piridina |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| JP7646653B2 (ja) * | 2019-11-22 | 2025-03-17 | エフ． ホフマン－ラ ロシュ アーゲー | ピロリジン誘導体 |
| KR20250057919A (ko) * | 2020-04-29 | 2025-04-29 | 릴레이 테라퓨틱스, 인크. | PI3Kα 억제제 및 이의 사용 방법 |
| CN112174869B (zh) * | 2020-10-12 | 2023-04-25 | 蔡霈 | N-苯乙酰基-2-羟甲基吡咯烷-2-甲酰胺的制备方法及其药用用途 |
| EP4236928A4 (en) * | 2020-10-30 | 2024-08-28 | 1Cbio, Inc. | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND THEIR USES |
| US20220354862A1 (en) * | 2021-05-04 | 2022-11-10 | Mind Medicine, Inc. | Liposome delivery of psychedelics |
| JP2025530462A (ja) | 2022-09-23 | 2025-09-11 | セレベル・セラピューティクス・エル・エル・シー | エムラクリジンの結晶形態、その調製方法及びその使用 |
| TW202432557A (zh) * | 2022-10-28 | 2024-08-16 | 大陸商紐歐申醫藥（上海）有限公司 | 一種含氮雜環化合物、其藥學上可接受的鹽及其製備方法與應用 |
| CN120641414A (zh) * | 2022-12-16 | 2025-09-12 | 卡鲁娜治疗学有限公司 | 经取代的四氢吡咯并-吡啶酮化合物及其在治疗医学病状中的用途 |
| WO2024130065A1 (en) * | 2022-12-16 | 2024-06-20 | Karuna Therapeutics, Inc. | Substituted dihydropyrrolo[3, 4-d]pyrimidine compounds and their use in treating medical conditions |
| EP4634194A1 (en) * | 2022-12-16 | 2025-10-22 | Karuna Therapeutics, Inc. | Substituted dihydropyrrolo [3, 4-d] pyrimidine compounds and their use in treating medical conditions |
| AU2023398924A1 (en) * | 2022-12-16 | 2025-06-26 | Karuna Therapeutics, Inc. | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions |
| WO2024230794A1 (zh) * | 2023-05-11 | 2024-11-14 | 中国药科大学 | 氮杂环丁烷衍生物、其制备方法及其医药用途 |
| CN116693437A (zh) * | 2023-06-15 | 2023-09-05 | 安徽大学 | 一种N-Boc-3-氮杂环丁烷乙酸的合成方法 |
| WO2024260386A1 (zh) * | 2023-06-20 | 2024-12-26 | 西藏海思科制药有限公司 | 毒蕈碱m4受体激动剂及其用途 |
| WO2025055965A1 (zh) * | 2023-09-13 | 2025-03-20 | 中国药科大学 | 氮杂环丁烷衍生物、其制备方法及其医药用途 |
| WO2025055970A1 (zh) * | 2023-09-15 | 2025-03-20 | 江苏恩华药业股份有限公司 | 氮杂环丁烷衍生物、其制备方法及其医药用途 |
| WO2025083630A1 (en) | 2023-10-19 | 2025-04-24 | Suven Life Sciences Limited | Heteroaromatic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) |
| WO2025099660A1 (en) | 2023-11-10 | 2025-05-15 | Suven Life Sciences Limited | Piperidine substituted compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) |
| WO2025103475A1 (zh) * | 2023-11-17 | 2025-05-22 | 上海翰森生物医药科技有限公司 | 杂环羰基类衍生物调节剂、其制备方法和应用 |
| WO2025122811A1 (en) * | 2023-12-07 | 2025-06-12 | Acadia Pharmaceuticals Inc. | M4 positive allosteric modulators |
| WO2025131049A1 (en) * | 2023-12-21 | 2025-06-26 | Ignis Therapeutics (Suzhou) Limited | Dihydro-pyrrolo-pyridine derivatives and uses thereof |
| WO2025134078A1 (en) | 2023-12-22 | 2025-06-26 | Suven Life Sciences Limited | Organic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) |
| TW202525292A (zh) * | 2023-12-27 | 2025-07-01 | 大陸商宜昌人福藥業有限責任公司 | 稠合嘧啶環化合物、藥物組合物及其應用 |
| WO2025145091A1 (en) | 2023-12-29 | 2025-07-03 | Pfizer Inc. | Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases |
| WO2025201078A1 (zh) * | 2024-03-25 | 2025-10-02 | 四川科伦药物研究院有限公司 | 化合物、包含其的药物组合物及其制备方法和用途 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994017197A1 (fr) | 1993-01-25 | 1994-08-04 | Takeda Chemical Industries, Ltd. | ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| EP2305709A1 (en) | 1997-04-09 | 2011-04-06 | Intellect Neurosciences, Inc. | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| KR100767146B1 (ko) | 2000-02-24 | 2007-10-15 | 워싱톤 유니버시티 | Ａβ 펩티드를 격리시키는 인간화 항체 |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| NZ544691A (en) | 2000-11-03 | 2007-12-21 | Proteotech Inc | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants |
| US20040192898A1 (en) | 2001-08-17 | 2004-09-30 | Jia Audrey Yunhua | Anti-abeta antibodies |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| MXPA05003621A (es) | 2002-10-09 | 2005-10-19 | Rinat Neuroscience Corp | Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos. |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| JP2006527756A (ja) | 2003-06-19 | 2006-12-07 | ファイザー・プロダクツ・インク | Ｎｋ１拮抗薬 |
| CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| CA2555071A1 (en) | 2004-02-02 | 2005-09-01 | Pfizer Products Inc. | Histamine-3 receptor modulators |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| EP1807434B1 (en) | 2004-10-25 | 2010-08-25 | Eli Lilly And Company | Thienopyridines as allosteric potentiators of the m4 muscarinic receptor |
| WO2006069081A2 (en) | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY |
| UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| BRPI0609225A2 (pt) | 2005-05-12 | 2010-03-09 | Pfizer | formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas |
| WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
| CA2608672A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| CA2603830A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Co Llc | PYRIDINE [2,3-B] PYRAZINONES |
| WO2006136924A1 (en) | 2005-06-22 | 2006-12-28 | Pfizer Products Inc. | Histamine-3 receptor antagonists |
| TW200713011A (en) | 2005-09-30 | 2007-04-01 | Hon Hai Prec Ind Co Ltd | System, method and electrical apparatus for data transferring |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| US20090163482A1 (en) | 2006-03-13 | 2009-06-25 | Mchardy Stanton Furst | Tetralines antagonists of the h-3 receptor |
| SI2013208T1 (sl) | 2006-04-21 | 2011-09-30 | Pfizer Prod Inc | Piridin(3,4-b)pirazinoni |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| CN1869036A (zh) * | 2006-06-30 | 2006-11-29 | 中国药科大学 | 7－取代－3－氯吡咯并[3,4－b]吡啶化合物 |
| EP2124933B1 (en) | 2007-01-22 | 2012-10-17 | Pfizer Products Inc. | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
| US8664234B2 (en) | 2010-10-04 | 2014-03-04 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone M1 receptor positive allosteric modulators |
| AR083855A1 (es) * | 2010-11-15 | 2013-03-27 | Abbott Lab | Inhibidores de nampt y rock |
| WO2012138845A1 (en) * | 2011-04-08 | 2012-10-11 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| JP6240063B2 (ja) * | 2011-04-28 | 2017-11-29 | ザ ブロード インスティテュート， インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| EP2780337B1 (en) * | 2011-11-15 | 2017-12-20 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as gpr119 agonists |
| US8741892B2 (en) * | 2011-12-05 | 2014-06-03 | Boehringer Ingelheim International Gmbh | Compounds |
| US8642774B2 (en) * | 2011-12-08 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Compounds |
| EP3321257A1 (en) | 2012-02-23 | 2018-05-16 | Vanderbilt University | Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| WO2014035829A1 (en) * | 2012-08-31 | 2014-03-06 | Vanderbilt University | Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators |
| US20160200733A1 (en) | 2013-08-23 | 2016-07-14 | Vanderbilt University | Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| US9637498B2 (en) * | 2013-08-23 | 2017-05-02 | Vanderbilt University | Substituted thieno[2,3-C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| US11497586B2 (en) | 2014-03-21 | 2022-11-15 | Align Technology, Inc. | Segmented orthodontic appliance with elastics |
| SMT202400446T1 (it) * | 2014-02-06 | 2024-11-15 | Nxera Pharma Uk Ltd | Composti aza biciclici come agonisti del recettore muscarinico |
-
2017
- 2017-06-15 EP EP17733044.6A patent/EP3478679B1/en active Active
- 2017-06-15 ES ES17733044T patent/ES2878160T3/es active Active
- 2017-06-15 PL PL17733044T patent/PL3478679T3/pl unknown
- 2017-06-15 CN CN201780053245.2A patent/CN109641898B/zh active Active
- 2017-06-15 HU HUE17733044A patent/HUE054857T2/hu unknown
- 2017-06-15 PT PT177330446T patent/PT3478679T/pt unknown
- 2017-06-15 DK DK17733044.6T patent/DK3478679T3/da active
- 2017-06-15 SG SG11201811712QA patent/SG11201811712QA/en unknown
- 2017-06-15 EP EP21167379.3A patent/EP3872078A1/en active Pending
- 2017-06-15 KR KR1020197002851A patent/KR102470497B1/ko active Active
- 2017-06-15 AU AU2017286868A patent/AU2017286868B2/en active Active
- 2017-06-15 JP JP2018568716A patent/JP7046018B2/ja active Active
- 2017-06-15 MX MX2019000231A patent/MX386258B/es unknown
- 2017-06-15 WO PCT/IB2017/053565 patent/WO2018002760A1/en not_active Ceased
- 2017-06-28 TW TW106121650A patent/TWI736642B/zh active
- 2017-06-28 CA CA2972070A patent/CA2972070A1/en active Pending
- 2017-06-29 US US15/637,071 patent/US10604519B2/en active Active
- 2017-06-30 UY UY0001037311A patent/UY37311A/es not_active Application Discontinuation
-
2018
- 2018-12-23 IL IL263912A patent/IL263912B/en unknown
-
2019
- 2019-01-03 PH PH12019500004A patent/PH12019500004A1/en unknown
- 2019-01-24 ZA ZA2019/00519A patent/ZA201900519B/en unknown
-
2020
- 2020-02-21 US US16/797,966 patent/US20200207762A1/en not_active Abandoned
-
2021
- 2021-06-01 US US17/335,666 patent/US11905284B2/en active Active
-
2023
- 2023-02-21 US US18/112,156 patent/US20230192690A1/en not_active Abandoned
- 2023-12-07 US US18/532,547 patent/US20240190869A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201900519B (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| IL267082A (en) | Systems and methods for the treatment of neurological disorders | |
| IL265902A (en) | Complex mixtures containing cannabinoids for the treatment of neurodegenerative diseases | |
| IL264641A (en) | Acetyl-leucine for use in the treatment of neurodegenerative diseases | |
| IL256380A (en) | Vesicular monoamine transporter 2 inhibitors for the treatment of neurological diseases or disorders | |
| SI3728271T1 (sl) | Makrociklične spojine za zdravljenje bolezni | |
| HRP20210518T1 (hr) | Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava | |
| IL248732B (en) | Compounds for the treatment of ophthalmological diseases and disorders | |
| IL269174A (en) | Methods for treating binding-mediated diseases or disorders | |
| IL273705A (en) | Benzothiazole compounds and methods of using them for the treatment of neurodegenerative diseases | |
| IL267818A (en) | Methods for treating neurological disorders | |
| IL263188B (en) | Treatment for Parkinson's disease | |
| IL270114B1 (en) | Methods and compounds for the treatment of neurological diseases | |
| IL255506A (en) | A method for treating a neurological disease | |
| ZA201805407B (en) | Composition for the prevention or treatment of neurodegenerative diseases. | |
| SI3452465T1 (sl) | Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni | |
| ZA201907238B (en) | Compositions for treating neurodegenerative diseases | |
| AU2017300579A1 (en) | Therapeutic agents for neurological and psychiatric disorders | |
| SG11202005278PA (en) | Compounds for treating eye diseases and methods thereof | |
| HK40008377A (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| HK40007595B (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| HK40007595A (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| HK40067011A (zh) | 用於治疗神经系统疾病的方法 | |
| ZA201807944B (en) | Treatment for parkinson's disease | |
| HK40029057A (en) | Probenecid for use in treating epileptic diseases, disorders or conditions |